Research Article

Relationship Between Procalcitonin Serum Level and Septic Patient Mortality in Dr. Saiful Anwar General Hospital, Malang

Agustin Iskandar , Deasy Ayuningtyas Tandio, Yeni Ayu Prihastuti

Agustin Iskandar
Department of Clinical Pathology, Faculty of Medicine, Universitas Brawijaya, Lab Sentral Rumah Sakit Umum Dr. Saiful Anwar, Malang, Jawa Timur, Indonesia. Email: agustin_almi@yahoo.co.id

Deasy Ayuningtyas Tandio
Department of Clinical Pathology, Faculty of Medicine, Universitas Brawijaya, Lab Sentral Rumah Sakit Umum Dr. Saiful Anwar, Malang, Jawa Timur, Indonesia

Yeni Ayu Prihastuti
Department of Clinical Pathology, Faculty of Medicine, Universitas Brawijaya, Lab Sentral Rumah Sakit Umum Dr. Saiful Anwar, Malang, Jawa Timur, Indonesia
Online First: December 01, 2020 | Cite this Article
Iskandar, A., Tandio, D., Prihastuti, Y. 2020. Relationship Between Procalcitonin Serum Level and Septic Patient Mortality in Dr. Saiful Anwar General Hospital, Malang. Intisari Sains Medis 11(3): 963-966. DOI:10.15562/ism.v11i3.829


Background: Procalcitonin is more frequently analyzed for sepsis diagnosis. Procalcitonin shows a tendency to increase as sepsis worsens. However, published studies investigating the correlation between procalcitonin and mortality in an adult patient with sepsis in Indonesia were lacking. This research aims to know the relationship between procalcitonin and mortality in sepsis.

Methods: A prospective cohort study was conducted in Dr. Saiful Anwar Public General Hospital, Malang, Indonesia from March to November 2018. During the study period, patients diagnosed with sepsis according to JAMA Sepsis-3 were tested for procalcitonin using Cobas e411 ECLIA method. The demographic and mortality data were acquired from the patients’ medical record. The statistical analysis was done with SPSS v.23, ? = 0.05.

Results: From a total of 69 subjects, 43 did not survive (62.32%). The procalcitonin serum level is significantly higher in the non-survivors than the survivors (37.77 ng/mL vs. 3.07 ng/mL, p=0.016). The Spearman’s rank correlation test showed r=0.293 (p=0.015). Using a cutoff point of 2 ng/mL, the relative risk is 2.77 (0.950-8.078).

Conclusion: There is a statistically significant weak relationship between procalcitonin and mortality, in which patients with procalcitonin equal or more than 2 ng/mL were 2.77 times more likely not to survive sepsis.

References

Balk RA, Kadri SS, Cao Z, Robinson SB, Lipkin C, Bozzette SA. Effect of Procalcitonin Testing on Health-care Utilization and Costs in Critically Ill Patients in the United States. Chest. 2017;151(1):23–33.

Davies J. Procalcitonin. J Clin Pathol. 2015;68(9):675–9.

Matsumura Y, Nakada TA, Abe R, Oshima T, Oda S. Serum procalcitonin level and SOFA score at discharge from the intensive care unit predict post-intensive care unit mortality: A prospective study. PLoS One. 2014;9(12):1–13.

Arora S, Singh P, Singh PM, Trikha A. Procalcitonin levels in survivors and nonsurvivors of sepsis: Systematic review and meta-analysis. Shock. 2015;43(3):212–21.

Lima SSS, Nobre V, de Castro Romanelli RM, Clemente WT, da Silva Bittencourt HN, Melo ACM, et al. Procalcitonin-guided protocol is not useful to manage antibiotic therapy in febrile neutropenia: a randomized controlled trial. Ann Hematol. 2016;95(7):1169–76.

Katakam N, Durgaraju S. Semi-Quantitative Procalcitonin Kit for Evaluating Severity and Predicting Mortality in Sepsis. J Evid Based Med Healthc. 2018;5(10):878–81.

Iskandar A, Arthamin MZ, Indriana K, Anshory M, Hur M, Di Somma S. Comparison between presepsin and procalcitonin in early diagnosis of neonatal sepsis. J Matern Neonatal Med. 2018;(May):1–6.

Jufitriani Ismy, Lubis M, Mutiara E, Yani GN, Trisnawati Y. PELOD score, serum procalcitonin, and lactate levels in pediatric sepsis Jufitriani. Pediatr Indones. 2015;55(6):293–6.

Dahlan MS. Besar Sampel dan Cara Pengambilan Sampel dalam Penelitian Kedokteran dan Kesehatan. 3rd ed. Jakarta: Salemba Medika; 2009.

Self WH, Grijalva CG, Williams DJ, Woodworth A, Balk RA, Fakhran S, et al. Procalcitonin as an Early Marker of the Need for Invasive Respiratory or Vasopressor Support in Adults With Community-Acquired Pneumonia. Chest. 2016;150(4):819–28.

Kim H, Hur M, Moon HW, Yun YM, Di Somma S. Multi-marker approach using procalcitonin, presepsin, galectin-3, and soluble suppression of tumorigenicity 2 for the prediction of mortality in sepsis. Ann Intensive Care. 2017;7(1):1–9.

Schuetz P, Birkhahn R, Sherwin R, Jones AE, Singer A, Kline JA, et al. Serial procalcitonin predicts mortality in severe sepsis patients: Results from the multicenter procalcitonin monitoring SEpsis (MOSES) Study. Crit Care Med. 2017;45(5):781–9.

Schuetz P, Wirz Y, Sager R, Christ-Crain M, Stolz D, Tamm M, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis. 2018;18(1):95–107.

Aygun F. Procalcitonin Value Is an Early Prognostic Factor Related to Mortality in Admission to Pediatric Intensive Care Unit. Crit Care Res Pract. 2018;2018:1–5.

Rumende CM, Mahdi D. Role of combined procalcitonin and lipopolysaccharide-binding protein as prognostic markers of mortality in patients with ventilator-associated pneumonia. Acta Med Indones. 2013;45(2):89–93.

Jain S, Sinha S, Sharma SK, Samantaray JC, Aggrawal P, Vikram NK, et al. Procalcitonin as a prognostic marker for sepsis: a prospective observational study. BMC Res Notes. 2014;7:458.

Gluck E, Nguyen HB, Yalamanchili K, McCusker M, Madala J, Corvino FA, et al. Real-world use of procalcitonin and other biomarkers among sepsis hospitalizations in the United States: A retrospective, observational study. PLoS One. 2018;13(10):1–18.

Pepper DJ, Sun J, Rhee C, Welsh J, Powers JH, Danner RL, et al. Procalcitonin-Guided Antibiotic Discontinuation and Mortality in Critically Ill Adults: A Systematic Review and Meta-analysis. Chest. 2019;(March):1–10.


Article Views      : 112
PDF Downloads : 54